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Abstract 
Background: Previous studies have suggested that prediction models for mortality should be adjusted for additional 
risk factors beyond the Acute Physiology and Chronic Health Evaluation (APACHE) score. Our objective was to identify 
risk factors independent of APACHE II score and construct a prediction model to improve the predictive accuracy for 
hospital and intensive care unit (ICU) mortality.
Methods: We used data from a multicenter randomized controlled trial (PROTECT, Prophylaxis for Thromboembolism 
in Critical Care Trial) to build a new prediction model for hospital and ICU mortality. Our primary outcome was all‑
cause 60‑day hospital mortality, and the secondary outcome was all‑cause 60‑day ICU mortality.
Results: We included 3746 critically ill non‑trauma medical–surgical patients receiving heparin thromboprophylaxis 
(43.3 % females) in this study. The new model predicting 60‑day hospital mortality incorporated APACHE II score (main 
effect: hazard ratio (HR) = 0.97 for per‑point increase), body mass index (BMI) (main effect: HR = 0.92 for per‑point 
increase), medical admission versus surgical (HR = 1.67), use of inotropes or vasopressors (HR = 1.34), acetylsalicylic 
acid or clopidogrel (HR = 1.27) and the interaction term between APACHE II score and BMI (HR = 1.002 for per‑
point increase). This model had a good fit to the data and was well calibrated and internally validated. However, the 
discriminative ability of the prediction model was unsatisfactory (C index < 0.65). Sensitivity analyses supported the 
robustness of these findings. Similar results were observed in the new prediction model for 60‑day ICU mortality 
which included APACHE II score, BMI, medical admission and invasive mechanical ventilation.
Conclusion: Compared with the APACHE II score alone, the new prediction model increases data collection, is more 
complex but does not substantially improve discriminative ability.
Trial registration: ClinicalTrials.gov Identifier: NCT00182143
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Background
Mortality rates in critically ill patients are substantial, 
ranging from 5 to 40  %, depending on case mix [1–3]. 
Predicting mortality in critically ill patients is challeng-
ing, but can be helpful for general counseling, triaging, 
treatment decisions and end of life discussions [4, 5].
The Acute Physiology and Chronic Health Evaluation 
(APACHE) prognostic scoring system is a well-estab-
lished, validated tool for assessing the severity of illness 
and predicting hospital mortality using data obtained 
in the first 24  h of ICU admission [6–11]. To increase 
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predictive accuracy, APACHE has developed four gen-
erations of models [12–15]. Nevertheless, there may be 
wide variation and limited validation in the ability of 
APACHE system to predict mortality in different coun-
tries and populations [16–20]. Siontis et  al. reported 
a median AUC (the area under the receiver operating 
characteristic curve) of 0.77 for APACHE II model after 
conducting a systematic evaluation of predictive tools for 
all-cause mortality in critically ill patients [21]. Further-
more, the updated APACHE III and IV models include 
substantially more variables than APACHE II, with a cor-
respondingly increased data collection burden [7, 22].
Advances in prognostic science have identified addi-
tional risk factors for mortality for critically ill patients 
that are independent of measures of illness severity, 
such as body mass index (BMI) [23, 24] and sex [25–27]. 
Moreover, some evidence suggests that prediction mod-
els for mortality should be adjusted for the use of vaso-
pressors [28], prothrombin index [29, 30] and platelet 
count [31, 32]. Therefore, given the imperfect accuracy of 
the APACHE system and other potential risk factors for 
death, we aimed to identify risk factors independent of 
APACHE II score and construct and validate a new mor-
tality prediction model that would combine the APACHE 
II score with these additional factors. The primary objec-
tive of this study was to improve the accuracy of a pre-
diction model for 60-day hospital mortality in critically ill 
medical–surgical patients, based on the data from a mul-
ticenter randomized controlled trial, PROTECT (Prophy-
laxis for Thromboembolism in Critical Care Trial). Our 
secondary objective was to construct a prediction model 
for 60-day ICU mortality.
Methods
In this study, we followed the TRIPOD (transparent 
reporting of a multivariable prediction model for individ-
ual prognosis or diagnosis) statement [33] to report the 
prediction model including model development, model 
performance and model validation.
Patients and settings
PROTECT (ClinicalTrials.gov Identifier: NCT00182143) 
was an international randomized controlled trial (RCT) 
that was conducted in 67 ICUs in academic and commu-
nity hospitals from 2006 to 2010 in Canada, Australia, 
Brazil, Saudi Arabia, the USA and the UK, as described 
elsewhere [34]. The trial compared the effect of unfrac-
tionated heparin (UFH) 5000  IU twice daily versus the 
low molecular weight heparin (LMWH) dalteparin 
5000  IU once daily plus once-daily placebo on the pri-
mary outcome of proximal leg deep vein thrombosis.
Non-trauma medical–surgical critically ill patients 
were enrolled if they were at least 18  years of age, 
weighed ≥45 kg and were expected to remain in the ICU 
for at least 3  days. Exclusion criteria were: admission 
diagnoses of major trauma, neurosurgery or orthopedic 
surgery, uncontrolled hypertension (systolic blood pres-
sure >180 mm Hg or diastolic blood pressure >110 mm 
Hg) for at least 12 h, major bleeding within the last week 
unless definitively treated, hemorrhagic stroke, coagu-
lopathy (international normalized ratio >2 times upper 
limit of normal or activated partial thromboplastin time 
>2 times the upper limit of normal), severe thrombocy-
topenia (platelet count <75 × 109/L), need for therapeu-
tic anticoagulation, heparin administration in the ICU 
for at least 3 days, contraindication to heparin or blood 
products, pregnancy, life-support limitation, life expec-
tancy ≤7 days or enrollment in another related trial [34, 
35]. All patients, families, clinicians, research person-
nel and the trial biostatistician were blind to treatment 
allocation. Patients were followed up to death or hospital 
discharge.
Outcome measures
During the trial follow-up, the vital status was docu-
mented in the ICU and in hospital. In this study, the pri-
mary outcome was 60-day hospital mortality. Patients 
survived longer than 60  days in hospital or discharged 
from hospital were censored. The secondary outcome 
was 60-day ICU mortality, and patients survived long 
than 60  days in ICU or discharged from the ICU were 
censored.
Potential predictors
Based on the data recorded in PROTECT and our a pri-
ori plan, potential risk factors for death included base-
line variables (APACHE II score, sex, BMI, history of 
malignancy, type of admission and diagnosis of sepsis 
on admission), use of UFH and interventions within the 
first 24  h of ICU admission (use of inotropes or vaso-
pressors, invasive mechanical ventilation, dialysis and 
pharmacologic cointerventions). The APACHE II score 
[13] has three parts: an acute physiology score (up to 60 
points), an age point (0–6) and a chronic health score 
(0–5). The acute physiology score is composed of 12 
physiologic variables: creatinine (0–8 points); Glasgow 
Coma Scale (0–12 points); ten other variables including 
temperature, mean arterial pressure, heart rate, respira-
tory rate, oxygenation, arterial pH, serum sodium, potas-
sium, hematocrit and white blood cell count (0–4 points 
each). The maximum total APACHE II score is 71 points, 
and a higher score indicates a higher predicted prob-
ability of death. The type of admission was categorized 
as either surgical or medical. Pharmacologic cointerven-
tions included the use of a statin, and acetylsalicylic acid 
or clopidogrel.
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Statistical analyses
In this study, all analyses were conducted using STATA 
version 12 (Stata Corp., College Station, TX, USA). Data 
were summarized using the mean and standard devia-
tion (SD), or median and interquartile range (IQR) or 
frequency and percentages. Comparisons between the 
patients who died and survived for the duration of hospi-
tal stay were made by using Student’s t test for continuous 
variables and Chi-square test for categorical variables, 
respectively. If <10 % of observations on a variable were 
missing, we imputed the missing values using the mean 
or median. If ≥10 % of data were missing, multiple impu-
tations were performed, assuming they were missing at 
random [36].
Identification of risk factors independent of APACHE II 
score and model development
To identify risk factors independent of APACHE II score, 
data were first randomly split into a training (deriva-
tion) set and a validation set stratifying by participating 
trial centers. The derivation set and validation set had an 
approximately equal sample size. In the derivation set, to 
avoid multicollinearity, we pruned the candidate predic-
tors of those with a variance inflation factor (VIF) of no 
less than 4 [37, 38]. Cox proportional hazards regression 
was conducted to examine associations with death using 
the backward elimination approach [37], after adjustment 
for the APACHE II score, with a two-sided alpha value of 
0.05. Hazard ratios (HRs) were used to quantify the rela-
tionship between risk factors and death. Both a statistical 
test of proportional hazards assumption and a graphical 
examination using Schoenfeld residuals were performed 
to test the proportional hazards assumption of the Cox 
regression models [39].
In the derivation set, the new prediction model for 
60-day hospital mortality was constructed by combining 
the APACHE II score and the other risk factors identified 
above into a Cox regression model. Additionally, all the 
two-way interactions between the predictors in the new 
prediction model were tested. Significant interactions 
with an a priori alpha value of 0.05 were then added into 
the model to finalize the prediction model.
For 60-day ICU mortality, identification of risk factors 
independent of APACHE II score and construction of a 
new prediction model were performed in the whole data-
set following the same process.
Model performance
For succinctness, we defined three models for hospital 
and ICU mortality in this study: Model 1 which included 
the APACHE II score only; Model 2 that included the 
other risk factors only; and Model 3, as the new predic-
tion model, which combined APACHE II score and the 
other risk factors. To assess the calibration of all the 
three models for 60-day hospital mortality in the deriva-
tion set, we calculated the standardized mortality ratio 
(SMR) by dividing the observed death risk by the pre-
dicted mortality. To obtain the 95 % confidence intervals 
(CIs) for SMRs, first we treated the observed mortality as 
a Poisson variable, and then divided its 95 % confidence 
limits by the predicted mortality [40]. For Model 1 and 
Model 3, we also compared and plotted the predicted and 
observed risks of death across each 10th of observed risk 
[41], in which the observed risk was obtained from the 
Kaplan–Meier product-limit estimate.
Model goodness-of-fit was evaluated using a Gron-
nesby and Borgan test with ten groups based on the pre-
dicted risk score, where a nonsignificant result indicated 
no evidence of lack of fit to the data [42]. The Akaike 
information criterion (AIC) was used to evaluate and 
compare the goodness-of-fit between the three models; a 
smaller AIC value indicated a better model [43]. The like-
lihood ratio test was also performed for model compari-
son. To measure discrimination, we calculated a Harrell’s 
C index for each model [37, 44].
For 60-day ICU mortality, performance of the three 
models was assessed and compared using the whole 
dataset.
Model validation for hospital mortality
We used the validation set to assess the internal valida-
tion of all the three models [45]. The evaluation of cali-
bration, goodness-of-fit and discrimination was again 
performed in the validation set [45, 46].
Sensitivity analyses
To assess the robustness of findings, we performed a 
sensitivity analysis by using restricted cubic splines for 
continuous predictors in the new model [37]. Another 
sensitivity analysis was conducted using data for 30-day 
hospital and 30-day ICU mortality, and 90-day hospital 
and 90-day ICU mortality.
Exploratory analysis for hospital mortality
We applied and compared Model 3 and Model 1 in differ-
ent countries for 60-day hospital mortality in the whole 
dataset, as an exploratory analysis. Model performance 
was assessed separately in Canada, Saudi Arabia and Bra-
zil, USA and UK, and Australia.
Results
Baseline characteristics of participants
There were 3746 patients included for analyses. The mean 
age at baseline was 61.4 (SD: 16.5) years, and 43.3 % were 
females. The median survival of the 588 (15.7 %) patients 
who died in the ICU was 10  days. The median survival 
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of the 873 (23.3 %) patients who died during the hospital 
stay was 14 days.
The data were randomly split into a derivation set 
(n  =  1891) and a validation set (n  =  1855). Figure  1 
shows Kaplan–Meier survival curves of 60-day hospital 
mortality in the derivation and validation sets, with no 
evidence of significant difference between the two sets 
(p value = 0.94 for log-rank test). Table 1 compares the 
baseline characteristics between the survivors and non-
survivors in the derivation and validation sets. In the 
derivation set, 22.6 % of participants (n = 428) died dur-
ing the whole follow-up period and their median survival 
time was 14  days (IQR 7.5–28). The median follow-up 
for survivors (n = 1463) was 18 days (IQR 11–33). Non-
survivors were significantly older than survivors (67.7 
vs. 59.3  years). The survivors had significantly lower 
APACHE II scores but higher BMI than non-survivors (p 
value <0.001). There were more patients receiving UFH 
in non-survivors (54.7  %) than in survivors (49.1  %). 
More non-surviving patients were admitted to ICU with 
the diagnoses of sepsis and medical reasons (p value 
<0.001). Non-survivors were significantly more likely to 
receive inotropes or vasopressors, invasive mechanical 
ventilation, dialysis and acetylsalicylic acid or clopidogrel 
within the first 24  h of ICU admission (p value <0.05). 
Similar comparisons were also found in the validation set 
between non-survivors and survivors, except for the pro-
portions of patients receiving UFH, invasive mechanical 
ventilation and dialysis, and the percentages of patients 
with malignancy and medical admission (Table 1). 
Model construction
Table 2 shows the predictors and their HRs included in 
the new model (Model 3) for 60-day hospital and 60-day 
ICU mortality. Based on the derivation set, BMI, medical 
admission, use of inotropes or vasopressors and acetyl-
salicylic acid or clopidogrel were significant risk factors 
for 60-day hospital mortality independently of APACHE 
II score; all of them except BMI increased the risk of 
hospital death. Model 3 for hospital mortality included 
APACHE II score (main effect: HR = 0.97, 95 % CI 0.92–
1.02 for per-point increase), BMI (main effect: HR = 0.92, 
95 % CI 0.88–0.97 for per-point increase), medical admis-
sion (HR = 1.67, 95 % CI 1.29–2.17), use of inotropes or 
vasopressors (HR = 1.34, 95 % CI 1.10–1.65), acetylsali-
cylic acid or clopidogrel (HR = 1.27, 95 % CI 1.02–1.59) 
and the interaction term between APACHE II score and 
BMI (HR  =  1.002, 95  % CI 1.000–1.004 for per-point 
increase) (Table 2).
Significant risk factors for 60-day ICU mortality inde-
pendent of APACHE II score were BMI, medical admis-
sion and invasive mechanical ventilation. Model 3 for 
ICU mortality included APACHE II score, BMI, medical 
admission and invasive mechanical ventilation, with a HR 
of 1.04, 0.98, 1.39 and 0.75, respectively. No significant 
interaction terms were identified for Model 3 (Table 2).
Model performance
Results and comparison of the three models for 60-day 
hospital mortality are shown in Table 3. In the deriva-
tion set, the goodness-of-fit test indicated no evidence 
of lack of fit to the data for Model 1 (p value =  0.68) 
for hospital mortality. However, the discriminative 
ability of Model 1 was poor (C index = 0.58). No evi-
dence for the inaccurate overall prediction of mortal-
ity by Model 1 was found, given that the SMR was not 
significantly different from 1 (SMR  =  1.003, 95  % CI 
0.959–1.050) (Table  3). Figure  2a displays predicted 
and observed hospital mortality in the derivation 
set across each 10th of the observed risk of death for 
Model 1, indicating Model 1 was well calibrated. Simi-
larly, Model 2 was a good fit and well calibrated in the 
derivation set, but its discriminative power was not 
high (C index = 0.62). Model 3 had a C index of 0.64 
and a SMR of 1.006 (95  % CI 0.961–1.052) (Table  3). 
The difference in C indices between Model 3 and 
Model 1 was significant (p value <0.001). Figure  2b 
shows predicted versus observed hospital mortality 
in the derivation set, which justified the calibration 
of Model 3. The smallest AIC was observed in Model 
3, indicating that Model 3 performed better than the 
other two models (Table  3). Likelihood ratio test also 
implied that Model 3 was a better fit than Model 1 and 
Model 2 (p values <0.001).
When the models were applied to the validation set, 
findings were unchanged. All the three models were well 
calibrated (Table  3; Fig.  3a for Model 1 and Fig.  3b for 
Model 3, respectively); nevertheless, their discriminative 
Fig. 1 Kaplan–Meier survival curves for 60‑day hospital mortality in 
derivation and validation sets
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power was not satisfactory (Table  3). Results from AIC 
and likelihood ratio tests presented that Model 3 was bet-
ter than Model 1 and Model 2.
Table  3 also displays results for 60-day ICU mortality 
using the whole dataset. The SMR was 1.003 and 1.004 for 
Model 1 and Model 3, respectively. Figure 4a and b also 
Table 1 Baseline characteristics of survivors and non-survivors in hospital in derivation and validation datasets
a Median follow-up: 18 days; interquartile range (IQR): 11–33 days
b Median survival time: 14 days; IQR 7.5–28 days
c Median follow-up: 19 days; IQR 11–37 days
d Median survival time: 15 days; IQR 7–29 days
e Student’s t test
f Chi-square test










Age (year): mean (SD) 59.3 (16.92) 67.7 (14.58) <0.001e 59.6 (16.07) 68.3 (14.40) <0.001e
Gender: n (%)
 Male 830 (56.93) 231 (54.10) 0.301f 786 (56.22) 266 (59.91) 0.172f
 Female 628 (43.07) 196 (45.90) 612 (43.78) 178 (40.09)
BMI (kg/m2): mean (SD) 28.5 (7.69) 27.1 (6.93) <0.001e 28.9 (8.39) 27.1 (6.78) <0.001e
Use of thromboprophylaxis: n (%)
 Unfractionated heparin 718 (49.08) 234 (54.67) 0.042f 696 (49.36) 225 (50.56) 0.659f
 Dalteparin 745 (50.92) 194 (45.33) 714 (50.64) 220 (49.44)
APACHE II score: mean (SD) 20.8 (7.61) 24.1 (7.59) <0.001e 20.6 (7.59) 24.5 (7.84) <0.001e
History of malignancy: n (%) 50 (3.43) 21 (4.92) 0.155f 47 (3.36) 32 (7.21) <0.001f
Medical admission: n (%) 1086 (74.23) 353 (82.48) <0.001f 1046 (74.18) 346 (77.75) 0.129f
Diagnosis of sepsis on admission: n (%) 208 (14.27) 90 (21.08) <0.001f 177 (12.66) 74 (16.67) 0.032f
Intervention within the first 24 h on admission: n (%)
 Inotropes or vasopressors 614 (42.20) 241 (56.44) <0.001f 579 (41.42) 243 (54.73) <0.001f
 Invasive mechanical ventilation 1207 (82.96) 373 (87.35) 0.030f 1149 (82.19) 380 (85.59) 0.097f
 Dialysis 57 (3.92) 45 (10.54) <0.001f 87 (6.22) 39 (8.78) 0.063f
 Acetylsalicylic acid or clopidogrel 290 (19.93) 113 (26.46) 0.004f 289 (20.49) 112 (25.23) 0.029f
 Statin 169 (11.62) 62 (14.52) 0.108f 199 (14.23) 59 (13.29) 0.617f
Table 2 Predictors for 60-day hospital mortality in the derivation dataset and for 60-day ICU mortality in the whole data-
set
a There were 390 60-day deaths in hospital in derivation cohort
b There were 573 60-day deaths in ICU in the whole cohort
c Not included in the model for ICU mortality; no interaction term in the model for ICU mortality





HR (95 % CI) p value HR (95 % CI) p value
BMI 0.92 (0.88–0.97) 0.003 0.98 (0.96–0.99) <0.001
Medical admission 1.67 (1.29–2.17) <0.001 1.39 (1.11–1.72) 0.003
Inotropes or vasopressors 1.34 (1.10–1.65) 0.005 –c –c
Acetylsalicylic acid or clopidogrel 1.27 (1.02–1.59) 0.035 –c –c
APACHE II score 0.97 (0.92–1.02) 0.241 1.04 (1.03–1.05) <0.001
APACHE II score*BMI 1.002 (1.000–1.004) 0.038 –c –c
Invasive mechanical ventilation –d –d 0.75 (0.58–0.97) 0.027
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support the calibration of Model 1 and Model 3, respec-
tively. The C index was not high, with a discriminative 
value of 0.61 and 0.64 for Model 1 and Model 3, respec-
tively. No significant difference in C indices between 
Model 3 and Model 1 was observed (p value = 0.16).
Results from sensitivity analysis using restricted cubic 
splines for BMI, APACHE II score and the interaction 
between them displayed similar findings from Model 3 for 
60-day hospital mortality, where the interior knots were 
located on 25 and 30 for BMI, and the medians for APACHE 
II score (21) and the interaction term (569), respectively 
(Table 4). Findings were also in good agreement with Model 
3 for 60-day ICU mortality when restricted cubic splines 
were used for BMI and APACHE II score (Table 4). Simi-
lar results of model construction and model performance 
were observed in another sensitivity analysis limiting data 
to 30-day hospital and 30-day ICU mortality (Appen-
dix Tables 6, 7) and restricting data to 90-day hospital and 
90-day ICU mortality (Appendix Tables 8, 9).
Exploratory analysis
An exploratory analysis was conducted by country for 
hospital mortality using the whole dataset (Table  5). 
Similar model performance was observed in different 
countries using Model 1 and Model 3. However, evidence 
indicated that Model 1 may under-predict risk of 60-day 
hospital death for patients in Saudi Arabia and Brazil 
(SMR = 1.155, 95 % CI 1.054–1.263).
Discussion
Main findings
Based on the data from an international thromboprophy-
laxis trial, we identified risk factors other than APACHE 
II score which predicted 60-day hospital mortality and 
60-day ICU mortality. We constructed a new predic-
tion model for mortality in critically ill patients receiving 
thromboprophylaxis. The new model was a good fit, well 
calibrated and internally validated. Results from sensitiv-
ity analyses supported the robustness of findings. How-
ever, the discriminative ability of the prediction model 
was not satisfactory.
In this study, we identified that higher BMI was sig-
nificantly related to decreased risk of hospital and ICU 
mortality (Table  2), which was congruent with previ-
ous studies [47–49]. The potentially protective effect of 
increased BMI on survival has been termed the obesity 
paradox or reverse epidemiology [50], but whether the 
observed association is causative remains unresolved [49, 
51, 52]. It has been postulated that higher body weight 
affords nutritional reserves that increase the chance of 
survival when patients are critically ill [53].
Medical admission was also found to be a significant 
independent risk factor for hospital and ICU death. 
Patients admitted for medical reasons may have more 
serious chronic morbidities not fully accounted for by 
APACHE chronic conditions, or have poorer prognoses 
when admitted to the ICU compared to those patients 
Table 3 Comparing three models in  model performance for  60-day hospital mortality in  the derivation and  validation 
dataset and for 60-day ICU mortality in the whole dataset
AIC Akaike information criterion, SMR standardized mortality ratio
a Based on Groennesby and Borgan test
b The other risk factors included BMI, medical admission, inotropes or vasopressors and acetylsalicylic acid or clopidogrel
c Model 3 consisted of BMI, medical admission, inotropes or vasopressors, acetylsalicylic acid or clopidogrel, APACHE II score and the interaction between BMI and 
APACHE II score
d The other risk factors included BMI, medical admission and invasive mechanical ventilation
e Model 3 consisted of BMI, medical admission, invasive mechanical ventilation and APACHE II score
Model performance Goodness-of-fit C index SMR (95 % CI)
p valuea AIC
Hospital mortality—derivation set (n = 1891)
 Model 1 (including APACHE II scores only) 0.68 5704 0.58 1.003 (0.959–1.050)
 Model 2 (including the other risk factors only)b 0.16 5359 0.62 1.002 (0.956–1.049)
 Model 3 (including both the other risk factors and APACHE II scores)c 0.90 5329 0.64 1.006 (0.961–1.052)
Hospital mortality—validation set (n = 1855)
 Model 1 (including APACHE II scores only) 0.37 5912 0.60 0.933 (0.890–0.978)
 Model 2 (including the other risk factors only)b 0.80 5765 0.59 1.019 (0.972–1.067)
 Model 3 (including both the other risk factors and APACHE II scores)c 0.88 5567 0.64 1.011 (0.966–1.060)
ICU mortality—the whole set (n = 3746)
 Model 1 (including APACHE II scores only) 0.75 8180 0.61 1.003 (0.972–1.036)
 Model 2 (including the other risk factors only)d 0.24 7821 0.58 1.001 (0.969–1.034)
 Model 3 (including both the other risk factors and APACHE II scores)e 0.74 7778 0.64 1.004 (0.972–1.038)
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selected for surgery. Also, we found that some interven-
tions within the first 24 h of ICU admission such as use 
of inotropes or vasopressors, and acetylsalicylic acid or 
clopidogrel, were associated with increased risk of hos-
pital mortality, reflecting more severe illness. However, 
invasive mechanical ventilation within the first 24  h on 
admission was associated with 25  % decreased risk of 
ICU death (Table  2). Evidence suggests that not using 
invasive mechanical ventilation could have negative 
effects on outcome by postponing necessary intubation; 
therefore, early initiation of invasive mechanical ventila-
tion may be related to decreased risk of death [54, 55].
Implications of the study
Given the previously acknowledged limited predictive 
accuracy of the APACHE II system for mortality, we 
sought to build a new prediction model for mortality 
for critically ill medical–surgical patients. In this study, 
the model including APACHE II score only (Model 1) 
had surprisingly low discriminative ability (Tables  3, 5), 
which has been documented previously [21]. The model 
that combined additional baseline characteristics and 
early ICU interventions may better assess patients’ illness 
severity and thus improve the estimated risk of mortal-
ity, compared with the APACHE II score alone. Never-
theless, though the prediction model had a significantly 
higher C index than APACHE II score in predicting risk 
of hospital mortality, adding more information such as 
BMI, medical admission and early pharmacologic inter-
ventions increased the discriminative accuracy to only 
a small extent (Table  3). The simplicity of the APACHE 
II score is a major reason why it remains the most com-
monly used severity scoring system globally in clinical 
practice as well as health research [4]. Compared with 
the APACHE II score alone, the utilization of a new 
model which increases data collection, is more complex 
but does not substantially improve discriminative ability. 
Therefore, the use of the new model would be limited to 
situations where a clinician or health services investigator 
was sufficiently dissatisfied with the APACHE II and was 
requiring an even minimally better model to predict risk 
of death in critically ill patients.
Fig. 2 Observed versus expected in derivation set for 60‑day hospital 
mortality: a results from Model 1; b results from Model 3 (solid diago-
nal line represents ideal calibration)
Fig. 3 Observed versus expected in validation set for 60‑day hospital 
mortality: a results from Model 1; b results from Model 3 (solid diago-
nal line represents ideal calibration)
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Comparison with other studies
Prediction models based on multivariate analyses typi-
cally use logistic regression analysis, due to the advantage 
of its simpler interpretation of the relationship between 
predictive factors and outcomes [56]. One study built a 
prediction model combining APACHE II score, a Model 
for End-Stage Liver Disease score, mechanical ventila-
tion and sex using logistic regression in ICU patients 
with end-stage liver disease [57]. They found that the new 
model was more accurate than APACHE II score alone 
(the area under the receiver operating characteristic 
curves (AUC): 0.86 versus 0.76) in prediction of hospital 
mortality [57]. Another cohort study employed an assess-
ment tool based on the PIRO (predisposition, insult, 
response and organ dysfunction) concept including 
Fig. 4 Observed versus expected in the whole dataset for 60‑day 
ICU mortality: a results from Model 1; b results from Model 3 (solid 
diagonal line represents ideal calibration)
Table 4 Sensitivity analyses of model performance in Model 3 using restricted cubic splines for continuous predictorsa 
for 60-day hospital and 60-day ICU mortality
AIC Akaike information criterion, SMR standardized mortality ratio
a Continuous predictors included BMI, APACHE score and the interaction between them for hospital mortality, and continuous predictors only included BMI and 
APACHE score for ICU mortality
b Based on Groennesby and Borgan test
c Model 3 for hospital mortality included BMI, medical admission, inotropes or vasopressors, acetylsalicylic acid or clopidogrel, APACHE II score and the interaction 
between BMI and APACHE II score
d Model 3 for ICU mortality consisted of BMI, medical admission, invasive mechanical ventilation and APACHE II score
Model performance Goodness-of-fit C index SMR (95 % CI)
p valueb AIC
Hospital mortality in derivation set (n = 1891)c 0.54 5691 0.63 1.007 (0.963–1.054)
Hospital mortality in validation set (n = 1855)c 0.51 5924 0.62 0.988 (0.943–1.034)
ICU mortality in the whole set (n = 3746)d 0.69 8177 0.64 1.005 (0.973–1.037)
Table 5 Exploratory analyses for  model performance 
of Models 1 and 3 in different countries for 60-day hospital 
mortality using the whole dataset
AIC Akaike information criterion, SMR standardized mortality ratio
a Based on Groennesby and Borgan test
b Model 1 included APACHE II score only
c Model 3 consisted of BMI, medical admission, inotropes or vasopressors, 
acetylsalicylic acid or clopidogrel, APACHE II score and the interaction between 
BMI and APACHE II score
Model performance Goodness-of-fit C index SMR (95 % CI)
p valuea AIC
Model 1b
 Canada (n = 2456) 0.41 7639 0.61 0.981 (0.942–1.021)
 Australia (n = 768) 0.11 1418 0.62 0.965 (0.897–1.037)
 USA and UK (n = 109) 0.64 130 0.68 0.982 (0.804–1.186)
 Saudi Arabia and Brazil 
(n = 413)
0.77 1713 0.55 1.155 (1.054–1.263)
Model 3c
 Canada (n = 2456) 0.88 7489 0.62 0.996 (0.956–1.037)
 Australia (n = 768) 0.80 1349 0.63 0.968 (0.898–1.043)
 USA and UK (n = 109) 0.41 125 0.71 0.981 (0.801–1.190)
 Saudi Arabia and Brazil 
(n = 413)
0.25 1660 0.63 1.099 (0.943–1.311)
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comorbidities, old age, multilobar opacities in chest radi-
ograph, shock, hypoxemia, bacteremia, acute renal fail-
ure and acute respiratory distress syndrome, to compare 
its model performance with APACHE II score in patients 
with community-acquired pneumonia [58]. The AUC of 
the PIRO score (0.88) was significantly higher than that 
of APACHE II score (0.75) in predicting 28-day ICU 
mortality [58]. Though it was difficult to directly compare 
our results with these models, given their different popu-
lations, settings, data and methodologies, these studies 
agreed with our findings in that adding more informa-
tion to build a new model would likely outperform the 
APACHE II score alone.
Limitations and strengths
This study was based on the data from a randomized 
thromboprophylaxis trial with strict inclusion and exclu-
sion criteria, which therefore limits the generalizability of 
its findings. For instance, the mortality rate in this study 
may be lower than in other studies, because patients with 
poor life expectancy were excluded in the trial protocol [34, 
35]. As well, the population upon which the new model 
was developed excluded patients who were at high risk of 
bleeding or if they were admitted to ICU because of major 
trauma, neurosurgery or orthopedic surgery [34, 35]. The 
latter criteria could also explain the apparent lower mortal-
ity associated with surgical patients compared to medical 
patients, as some of the more seriously ill surgical patients 
(e.g., patients with trauma, neurosurgical or orthopedic sur-
gery) were excluded from the study. In addition, we could 
only use the data included in the original trial database, and 
we could not subsequently capture other potentially impor-
tant indicators of illness severity including those that might 
have helped with the discrimination of this new model.
Strengths of this study include the international mul-
ticenter design, large sample size and standardized data 
collection. Moreover, we performed rigorous statistical 
analyses to build a new model and evaluate its perfor-
mance. Evidence from internal validation and sensitiv-
ity analyses indicated that the findings were internally 
validated and robust. Similar results from explanatory 
analyses in different countries also suggested the general-
izability and robustness of the model in this dataset using 
a heterogeneous group of patients.
Conclusion
Using data from critically ill medical–surgical patients 
receiving heparin thromboprophylaxis, we identify addi-
tional risk factors for mortality independent of APACHE 
II score and construct a new model to predict risk of 
death. The new model combining APACHE II score and 
other risk factors is a good fit, well calibrated, but with 
unsatisfactory discriminative power. Compared with the 
APACHE II score alone, the new prediction model which 
increases data collection, is more complex but does not 
substantially improve discriminative ability.
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Table 6 Predictors for 30-day hospital mortality in the derivation dataset and for 30-day ICU mortality in the whole data-
set
a There were 332 deaths for 30-day hospital mortality in derivation cohort
b There were 522 deaths for 30-day ICU mortality in the whole cohort
c Not included in the model for ICU mortality
d Not included in the model for hospital mortality
Predictors Hospital mortality (n = 1891)a ICU mortality (n = 3746)b
HR (95 % CI) p value HR (95 % CI) p value
BMI 0.97 (0.95–0.99) <0.001 0.97 (0.96–0.99) <0.001
Medical admission 1.86 (1.38–2.51) <0.001 1.41 (1.12–1.78) 0.003
Inotropes or vasopressors 1.45 (1.16–1.82) 0.001 –c –c
Acetylsalicylic acid or clopidogrel 1.22 (1.02–1.46) 0.037 –c –c
APACHE II score 1.03 (1.01–1.04) <0.001 1.04 (1.03–1.05) <0.001
Invasive mechanical ventilation –d –d 0.77 (0.59–0.99) 0.042
Table 7 Results for sensitivity analyses of model performance in the new model for 30-day hospital mortality and 30-day 
ICU mortality
AIC Akaike information criterion, SMR standardized mortality ratio
a Based on Groennesby and Borgan test
b The new model for 30-day hospital mortality included BMI, medical admission, inotropes or vasopressors, acetylsalicylic acid or clopidogrel and APACHE II score
c The new model for 30-day ICU mortality consisted of BMI, medical admission, invasive mechanical ventilation and APACHE II score
Model performance Goodness-of-fit C index SMR (95 % CI)
p valuea AIC
Hospital mortality in derivation set (n = 1891)b 0.74 4682 0.63 1.005 (0.960–1.051)
Hospital mortality in validation set (n = 1855)b 0.76 4789 0.65 1.006 (0.961–1.053)
ICU mortality in the whole set (n = 3746)c 0.65 7559 0.64 1.003 (0.971–1.036)
Table 8 Predictors for 90-day hospital mortality in the derivation dataset and for 90-day ICU mortality in the whole data-
set
a There were 405 deaths for 90-day hospital mortality in derivation cohort
b There were 581 deaths for 90-day ICU mortality in the whole cohort
c Not included in the model for ICU mortality
d Not included in the model for hospital mortality
Predictors Hospital mortality (n = 1891)a ICU mortality (n = 3746)b
HR (95 % CI) p value HR (95 % CI) p value
BMI 0.93 (0.88–0.97) 0.003 0.98 (0.96–0.99) <0.001
Medical admission 1.67 (1.29–2.17) <0.001 1.39 (1.12–1.73) 0.003
Inotropes or vasopressors 1.36 (1.11–1.67) 0.003 –c –c
Acetylsalicylic acid or clopidogrel 1.27 (1.02–1.59) 0.035 –c –c
APACHE II score 0.97 (0.92–1.02) 0.241 1.04 (1.02–1.05) <0.001
APACHE II score*BMI 1.002 (1.000–1.004) 0.038 –c –c
Invasive mechanical ventilation –d –d 0.75 (0.58–0.97) 0.026
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